(Q35781398)

10 August 2017

title

Druggability of Intrinsically Disordered Proteins (English)

1 reference

10 August 2017

2

Michele Vendruscolo

1 reference

10 August 2017

Priyanka Joshi

1

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 January 2015

1 reference

Advances in Experimental Medicine and Biology

10 August 2017

published in

1 reference

10 August 2017

volume

870

1 reference

10 August 2017

page(s)

383-400

1 reference

Small-molecule inhibitors of protein-protein interactions: progressing towards the dream

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Chemical kinetics for drug discovery to combat protein aggregation diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Structural biology. Versatility from protein disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Structural analysis of intrinsically disordered proteins by small-angle X-ray scattering

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Structural characterization of flexible proteins using small-angle X-ray scattering

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Low-resolution structures of transient protein-protein complexes using small-angle X-ray scattering.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Rational drug design via intrinsically disordered protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Protein misfolding, functional amyloid, and human disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

A hot spot of binding energy in a hormone-receptor interface

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Recent developments in fragment-based drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

The atomic structure of protein-protein recognition sites

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

c-Myc target genes involved in cell growth, apoptosis, and metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

The N-terminal domain of p53 is natively unfolded.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

The structural basis of protein folding and its links with human disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Chemical space and biology

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Drugs for 'protein clouds': targeting intrinsically disordered transcription factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Intrinsic disorder and protein function

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Flexible nets. The roles of intrinsic disorder in protein interaction networks.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Intrinsically unstructured proteins and their functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

The amyloid state of proteins in human diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Atomic structure and hierarchical assembly of a cross- amyloid fibril

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Deconstruction of a Nutlin: Dissecting the Binding Determinants of a Potent Protein–Protein Interaction Inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

ChEMBL: a large-scale bioactivity database for drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Introducing protein intrinsic disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

A decade of fragment-based drug design: strategic advances and lessons learned

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

NMR-based screening in drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Small-Molecule Inhibition of c-MYC:MAX Leucine Zipper Formation Is Revealed by Ion Mobility Mass Spectrometry

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Intrinsic disorder in cell-signaling and cancer-associated proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Drugs, their targets and the nature and number of drug targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

ZINC--a free database of commercially available compounds for virtual screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

A molecular dynamics ensemble-based approach for the mapping of druggable binding sites.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Principles of protein-protein interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

NMR-based screening: a powerful tool in fragment-based drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

An analytical solution to the kinetics of breakable filament assembly

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

The amyloid state and its association with protein misfolding diseases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Structural conservation of druggable hot spots in protein-protein interfaces

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Regulation of p53 stability by Mdm2

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Lead- and drug-like compounds: the rule-of-five revolution

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Intrinsic disorder in PTEN and its interactome confers structural plasticity and functional versatility

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

A novel inhibitor of amyloid β (Aβ) peptide aggregation: from high throughput screening to efficacy in an animal model of Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Differences in nucleation behavior underlie the contrasting aggregation kinetics of the Aβ40 and Aβ42 peptides

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

The expanding view of protein-protein interactions: complexes involving intrinsically disordered proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Intrinsically disordered proteins are potential drug targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

The impact of small molecule binding on the energy landscape of the intrinsically disordered protein C-myc

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Ordering of the N-terminus of human MDM2 by small molecule inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Mutant p53 in cancer: new functions and therapeutic opportunities

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Structural biology in fragment-based drug design

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

The rise of fragment-based drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Flexible nets: disorder and induced fit in the associations of p53 and 14-3-3 with their partners

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

31 March 2020

NMR in drug discovery

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Perspectives on NMR in drug discovery: a technique comes of age

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Biophysical techniques for ligand screening and drug design

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Intrinsically disordered proteins: from sequence and conformational properties toward drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Discovering high-affinity ligands for proteins: SAR by NMR

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Fragment-based lead discovery: challenges and opportunities

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Intrinsically disordered proteins: a 10-year recap

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Intrinsically disordered proteins and novel strategies for drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Unusual biophysics of intrinsically disordered proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Intrinsically Disordered Proteins in Human Diseases: Introducing the D 2 Concept

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Unfoldomics of human diseases: linking protein intrinsic disorder with diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Classification of intrinsically disordered regions and proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

pE-DB: a database of structural ensembles of intrinsically disordered and of unfolded proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Determination of conformationally heterogeneous states of proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Towards complete descriptions of the free-energy landscapes of proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

PubChem: a public information system for analyzing bioactivities of small molecules

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Novel strategies for drug discovery based on Intrinsically Disordered Proteins (IDPs)

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

De novo design of self-assembled hexapeptides as β-amyloid (Aβ) peptide inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Fragment-based drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Reaching for high-hanging fruit in drug discovery at protein-protein interfaces

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Privileged scaffolds for library design and drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

DrugBank: a comprehensive resource for in silico drug discovery and exploration

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

A peptide hairpin inhibitor of amyloid beta-protein oligomerization and fibrillogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

Identification of small-molecule binding pockets in the soluble monomeric form of the Aβ42 peptide

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20164-1_13

10.1007/978-3-319-20164-1_13

31 March 2020

Identifiers

DOI

1 reference

10 August 2017

1 reference